https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-01 / Can J Neurol Sci 2016 Jul;43(4):494-502
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-01 / Can J Neurol Sci 2016 Jul;43(4):494-5022016-07-01 00:00:002019-02-15 08:47:28Immunological Aspects of Malignant Gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-04 / J Clin Oncol 34, 2016 (suppl; abstr 2039)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-04 / J Clin Oncol 34, 2016 (suppl; abstr 2039)2016-06-04 12:03:342019-07-17 12:03:56Association of increased survival in glioblastoma patients treated with dendritic cell vaccinations and temozolomide with increased activity of NK cells and ABCC3 expression.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-01 / Expert Opin Emerg Drugs 2016 Jun;21(2):133-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-01 / Expert Opin Emerg Drugs 2016 Jun;21(2):133-452016-06-01 00:00:002016-06-01 00:00:00Emerging immunotherapies for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-03-02 / Sci Transl Med 2016 Mar;8(328):328ra27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-03-02 / Sci Transl Med 2016 Mar;8(328):328ra272016-03-02 00:00:002022-09-29 14:06:28Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-09-14 / Int J Hyperthermia 2015;31(7):784-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-09-14 / Int J Hyperthermia 2015;31(7):784-922015-09-14 00:00:002019-03-27 11:37:15Electro-hyperthermia inhibits glioma tumorigenicity through the induction of E2F1-mediated apoptosis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-09-11 / Oncoimmunology 2016 Feb;5(2):e1083669
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-09-11 / Oncoimmunology 2016 Feb;5(2):e10836692015-09-11 00:00:002021-11-15 13:26:23Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-27 / Biomed Res Int 2015;2015:842923
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-27 / Biomed Res Int 2015;2015:8429232015-08-27 00:00:002021-11-15 13:26:51Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-27 / J. Neurooncol. 2015 Oct;125(1):65-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-27 / J. Neurooncol. 2015 Oct;125(1):65-742015-08-27 00:00:002019-02-15 08:47:20Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-07 / J. Neurosurg. 2015 Oct;123(4):989-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-07 / J. Neurosurg. 2015 Oct;123(4):989-972015-08-07 00:00:002019-02-15 08:47:20Dendritic cell-based immunotherapy targeting Wilms‘ tumor 1 in patients with recurrent malignant glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-17 / J Clin Oncol 33, 2015 (suppl; abstr e13030)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-17 / J Clin Oncol 33, 2015 (suppl; abstr e13030)2015-06-17 12:08:122019-07-17 12:08:33Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).
